Enanta Pharmaceuticals (STU:9EP) Tariff Resilience Score: 7/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
58 GF Score
Price €11.50
GF Value €7.65
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Tariff Resilience Score?

Enanta Pharmaceuticals STU:9EP 58 Tariff Resilience Score is 7 as of Jul. 16, 2026. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,370 Biotechnology companies, Enanta Pharmaceuticals ranks better than 90.36% on this metric.

Enanta Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Enanta Pharmaceuticals has Enanta Pharmaceuticals has limited exposure to tariffs due to its focus on drug development rather than manufacturing. Its supply chain is less dependent on international trade, and it can leverage alternative suppliers. However, any changes in tariffs on raw materials could impact costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Enanta Pharmaceuticals might have Highly Resilient.

Enanta Pharmaceuticals  (STU:9EP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Enanta Pharmaceuticals Tariff Resilience Score Related Terms

STU:9EP vs PBYI, IPSC, BNTC: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enanta Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Tariff Resilience Score falls into.


STU:9EP
58GF Score
Enanta Pharmaceuticals Inc STU:9EP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Enanta Pharmaceuticals (STU:9EP) has a Tariff Resilience Score of 7 as of Jul. 16, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Enanta Pharmaceuticals ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Enanta Pharmaceuticals' Tariff Resilience Score too high?
Enanta Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Enanta Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, Enanta Pharmaceuticals ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Tariff Resilience Score compare to PBYI and IPSC?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #132 out of 1370 companies for Tariff Resilience Score. This places Enanta Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Enanta Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enanta Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enanta Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.65, compared to a current price of €11.50 — trading 50.3% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current Tariff Resilience Score is 7 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.50 is trading 50.3% above its estimated GF Value™ of €7.65. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • Tariff Resilience Score: 7
  • GF Value™: €7.65 vs. price of €11.50 (50.3% above fair value)
  • GF Score™: 58/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1370)

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score

Get the complete analysis for STU:9EP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.50
Price
€7.65
GF Value